Does low LH with low free and bioavailable testosterone indicate secondary hypogonadism?

Pathophysiology and mechanistic pathways

• Hypothalamic-pituitary failure: A biochemical profile presenting with low luteinizing hormone (LH) and low free or bioavailable testosterone serves as the classic laboratory signature of secondary (hypogonadotropic) hypogonadism.
• GnRH-LH-Leydig axis disruption: Under physiological conditions, pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus triggers pituitary gonadotrophs to release LH. LH then binds to LH receptors on testicular Leydig cells to stimulate steroidogenesis. In secondary hypogonadism, diminished GnRH pulsatility or pituitary dysfunction results in inadequate LH release, leaving structurally intact Leydig cells under-stimulated.

Diagnostic and clinical implications

• Impact of SHBG abnormalities: Sex hormone-binding globulin (SHBG) levels heavily influence total testosterone concentrations. In conditions such as obesity or metabolic syndrome, altered SHBG levels can mask true androgen status. Assessing free or bioavailable testosterone is highly recommended in borderline or equivocal cases to accurately reflect tissue-level hormone exposure.
• Identifying central etiologies: Documenting low free or bioavailable testosterone paired with low or "inappropriately normal" LH directs clinicians to investigate central causes rather than primary testicular failure. This biochemical signature guides the evaluation toward etiologies such as pituitary masses, hyperprolactinemia, iron overload, or functional hypothalamic suppression.

Bottom line

• Combined low LH and low free/bioavailable testosterone confirms secondary hypogonadism, signaling that testicular Leydig cells are under-stimulated due to a central hypothalamic-pituitary defect rather than primary testicular failure.